ArticleCureus2026
Association of Neutrophil-to-Lymphocyte Ratio With Early Diabetic Nephropathy in Patients With Type 2 Diabetes Mellitus.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundType 2 diabetes mellitus (T2DM) is a chronic condition associated with a range of complications, one of the most significant being diabetic nephropathy (DN). It is a leading cause of kidney failure, and its early detection is crucial for delaying disease progression. While traditional markers are commonly used, they often detect renal impairment only in more advanced stages. Since chronic inflammation is a key contributor to the development of diabetic complications, the neutrophil-to-lymphocyte ratio (NLR) may serve as a useful and cost-effective biomarker of early DN in patients with T2DM.
objectiveTo determine whether elevated NLR levels are associated with early markers of renal dysfunction, and to assess the predictive value of NLR in identifying early-stage DN in type 2 diabetic patients.
methodsA total of 126 T2DM patients satisfying the inclusion criteria were included in the study after taking informed consent. Subjects were divided into two groups based on the presence (66) and absence (60) of albuminuria. Fasting blood sugar, glycated hemoglobin, NLR, blood urea, serum creatinine, urinary albumin excretion, urinary albumin creatinine ratio, and estimated glomerular filtration rate were noted to assess renal function.
resultsA total of 126 patients diagnosed with type 2 diabetes were registered in our study. The mean NLR for patients without albuminuria was 1.96 ± 0.54, and for the DN group, it was 3.06 ± 0.98, which was significant (p < 0.001). Also, a strong positive correlation was seen between NLR and markers of early DN (r = 0.42, p = 0.001).
conclusionA significant correlation was found between NLR and markers of early DN in patients with T2DM. NLR may be considered a cost‑effective surrogate biomarker for the early detection of DN, enabling timely intervention strategies to mitigate progression of nephropathy in T2DM.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.